Kidney Transplantation Post-Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma.
Zahraa Khan, Darshana M Dadhania, Eugene Brailovski et al.
✦ AI-curated · Sources linked
Case in brief
A 71-year-old man with stage III multiple myeloma and end-stage kidney disease underwent ciltacabtagene autoleucel CAR T-cell therapy, achieving minimal residual disease (MRD)-negative status. One year later, he received a living donor kidney transplant. Post-transplant complications included hypogammaglobulinemia, cytopenia, BK viremia, and acute rejection, all managed effectively. At 17 months post-transplant, he maintains stable allograft function and MRD-negative complete hematologic remission.
Diagnostic / clinical pearl
This case illustrates the potential for successful kidney transplantation in multiple myeloma patients following effective CAR T-cell therapy, despite the associated risks.
Why it matters
The report emphasizes the evolving landscape of treatment options for multiple myeloma, highlighting the need for careful management of complications in the context of transplantation.